

---

**AMENDMENTS TO THE SPECIFICATION**

---

Page 9, after line 24, after **BRIEF DESCRIPTION OF THE DRAWINGS**, please amend as follows:

Fig. 1 is a graph of murine bone marrow stem cell proliferation and Fig. 2 is a graph of NO production in murine macrophage cells;

Figs. 3, 4 and 5 are graphs of Dextran-FITC conjugate take up by human dendritic cells differentiated from monocytes isolated from peripheral blood;

Fig 6 is a graph of CD40 surface marker expression;

Figs. 7, 8 and 9 are graphs of CD86, CD83 and CD80 surface marker expression, respectively, from human dendritic cells;

Figs. 10, 11 and 12 are graphs of OM-294-MP and OM-294-DP effects TNF- $\alpha$  and IL12 p70 production in supernatants of human dendritic cells culture;

Figs. 13, 14 and 15 are graphs of ELISA 2, 3 and 4 after the first, second and third immunization of mice with a malaria antigen (synthetic peptide Pb CS His6 242-310);

Fig. 16 is a graph of antibody titer before and after immunization of mice with a malaria antigen (synthetic peptide Pb CS His6 242-310);

Figs. 17 to 20 are graphs of ELISPOT IFN- $\gamma$  producing lymphocytes after immunization of mice with a malaria antigen (synthetic peptide Pb CS His6 242-310) and Fig. 21 is an electropherogram;

Figs. 22 to 29 are graphs of specific mouse antibodies IgG1, IgG2a, IgM directed to specific antigens;

Figs. 30(a) and 30(b) are graphs of anti-gp63 immune response and Figs. 31(a)  
and 31(b) are graphs of lymph node lymphocyte response;

Figs. 32(a) and 32(b) are graphs of anti-LmCPb immune response;

Figs. 33 to 38 are scheme outlining the synthetic processes of the invention;

Figs. 39 to 41 are graphs of ES-MS spectra Mass spectra of the compounds of the  
invention;

Fig. 42 and 43 are graphs of <sup>1</sup>H-NMR spectra of the compounds of the invention;

Figs 44 and 45 are graphs of <sup>13</sup>C-NMR spectra of the compounds of the  
invention;

Fig. 46 is a graph of and 47 are <sup>31</sup>P-NMR spectra of the compounds of the  
invention.